Hospital Sales Cycles and the Myth of “80% Confidence”

I once reviewed a MedTech pipeline where nearly every deal was listed at 80% probability.

Fourteen deals.
All 80%.

I asked why.

The answer was simple:

“They’re engaged.”

Engagement is not commitment.

Hospital sales cycles break traditional forecasting because they are multi-layered, political, and procedural.

Without discipline, pipelines become emotional.

Why MedTech Forecasting Is Different

In SaaS, you may deal with:

• A primary decision maker
• Defined budget owner
• 30–90 day cycle

In MedTech, you face:

• Clinical evaluation
• Budget committee timing
• Capital approval cycles
• Value analysis review
• Competitive trials
• Procurement contracts
• Implementation constraints

Each layer introduces delay risk.

If forecasting doesn’t reflect that complexity, misses are inevitable.

The Five Forecast Killers in MedTech

1. Single-Threaded Deals

If only one clinical champion supports you, you’re vulnerable.

Forecast should reflect multi-thread depth.

2. Undefined Budget Source

“Budget will come from somewhere” is not budget confirmation.

Stage progression requires financial clarity.

3. Committee Timing Unknown

If you don’t know when value analysis meets, you don’t know close timing.

4. Competitive Underestimation

Incumbent vendors are deeply embedded.

Displacement requires executive-level strategy.

5. Implementation Blind Spots

IT integration, training, rollout complexity — all affect close timing.

Building Forecast Discipline

Here’s what effective MedTech forecasting requires:

1. Defined Probability by Evidence, Not Emotion

Instead of asking, “How confident are you?”

Ask:

• Has budget been approved?
• Has value analysis been scheduled?
• Is procurement engaged?
• Is implementation timeline confirmed?

Probability increases only with validation.

2. Documented Close Plans

Every late-stage deal should have:

• Named decision makers
• Decision date
• Required next steps
• Competitive position
• Implementation readiness plan

If that’s missing, the deal is earlier than you think.

3. Historical Conversion Analysis

Know your:

• Stage-to-stage conversion rates
• Average cycle length
• Lost deal patterns
• Delay triggers

Forecast accuracy improves when history informs probability.

4. Weekly Executive Inspection

Forecast discipline must be led.

Not delegated.

Executives must ask hard questions:

• What evidence supports this close?
• What risk is unaddressed?
• What would derail this deal?

Inspection builds credibility.

Why This Matters to Investors

When investors ask for “revenue visibility,” they mean:

Can you explain why this revenue will land?

Not hope.
Not confidence.
Not enthusiasm.

Evidence.

Predictable revenue earns trust.

Trust earns patience.

Patience earns runway.

MedTech is complex.

That complexity is not an excuse for volatility.

It’s a reason for structure.